Non-vitamin K Antagonist Oral Anticoagulants Therapy for Atrial Fibrillation Patients Undergoing Electrophysiologic Procedures

Overview

Journal Eur Heart J Suppl

Publisher Oxford University Press

Date 2020 Oct 22

PMID 33088232

Citations 3

Authors

Jan Steffel

Affiliations

Soon will be listed here.

Abstract

Over the last 10 years since the introduction of non-vitamin K antagonist oral anticoagulants (NOACs) into routine clinical practice our experience with these drugs has increased tremendously, also in the context of patients undergoing electrophysiology procedures. While some open questions remain, the available evidence indicates that for the majority of cases, these interventions can safely be performed on NOACs if study-based standard operating procedures are in place and followed. This review summarizes the most current trial evidence and guidelines on the use of NOACs for patients undergoing cardioversion, atrial fibrillation ablation, and device implantations, based on previous work of the author and others.

Citing Articles

Periinterventional Management of Edoxaban in Major Procedures: Results from the DRESDEN NOAC REGISTRY.

Kohler C, Tittl L, Hansel U, Hammermuller E, Marten S, Naue C TH Open. 2023; 7(3):e251-e261.

PMID: 37746027 PMC: 10516686. DOI: 10.1055/s-0043-1774304.

Anticoagulant therapy during cardiovascular implantable electronic device procedures.

Daubaraite A, Marinskis G, Rackauskas G Postepy Kardiol Interwencyjnej. 2023; 19(2):99-112.

PMID: 37465619 PMC: 10351075. DOI: 10.5114/aic.2023.129207.

2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.

Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler K Europace. 2021; 23(10):1612-1676.

PMID: 33895845 PMC: 11636576. DOI: 10.1093/europace/euab065.

References

Plitt A, Ezekowitz M, De Caterina R, Nordio F, Peterson N, Giugliano R . Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol. 2016; 39(6):345-6. PMC: 6490822. DOI: 10.1002/clc.22537. View

Hansen M, Jepsen R, Olesen J, Ruwald M, Karasoy D, Gislason G . Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace. 2014; 17(1):18-23. DOI: 10.1093/europace/euu189. View

McIntyre W, Connolly S, Wang J, Masiero S, Benz A, Conen D . Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials. Eur Heart J. 2019; 40(36):3026-3032. DOI: 10.1093/eurheartj/ehz521. View

Gronberg T, Hartikainen J, Nuotio I, Biancari F, Ylitalo A, Airaksinen K . Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study). Am J Cardiol. 2016; 117(8):1294-8. DOI: 10.1016/j.amjcard.2016.01.024. View

Mincu R, Mahabadi A, Totzeck M, Rassaf T . Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation - a meta-analysis of more than 17000 patients. Sci Rep. 2019; 9(1):3011. PMC: 6395612. DOI: 10.1038/s41598-019-39925-5. View

Puwanant S, Varr B, Shrestha K, Hussain S, Tang W, Gabriel R . Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. J Am Coll Cardiol. 2009; 54(22):2032-9. DOI: 10.1016/j.jacc.2009.07.037. View

Giugliano R, Ruff C, Braunwald E, Murphy S, Wiviott S, Halperin J . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-104. DOI: 10.1056/NEJMoa1310907. View

Torn M, Rosendaal F . Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol. 2003; 123(4):676-82. DOI: 10.1046/j.1365-2141.2003.04652.x. View

Frederiksen A, Albertsen A, Christesen A, Vinter N, Frost L, Moller D . Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin. Europace. 2017; 20(7):1078-1085. DOI: 10.1093/europace/eux188. View

10.

Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. DOI: 10.1056/NEJMoa1009638. View

11.

January C, Samuel Wann L, Calkins H, Chen L, Cigarroa J, Cleveland Jr J . 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the.... Circulation. 2019; 140(2):e125-e151. DOI: 10.1161/CIR.0000000000000665. View

12.

Niku A, Shiota T, Siegel R, Rader F . Prevalence and Resolution of Left Atrial Thrombus in Patients With Nonvalvular Atrial Fibrillation and Flutter With Oral Anticoagulation. Am J Cardiol. 2018; 123(1):63-68. DOI: 10.1016/j.amjcard.2018.09.027. View

13.

Scherr D, Dalal D, Chilukuri K, Dong J, Spragg D, Henrikson C . Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2008; 20(4):379-84. DOI: 10.1111/j.1540-8167.2008.01336.x. View

14.

Ezekowitz M, Pollack Jr C, Halperin J, England R, VanPelt Nguyen S, Spahr J . Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018; 39(32):2959-2971. PMC: 6110194. DOI: 10.1093/eurheartj/ehy148. View

15.

Romero J, Husain S, Kelesidis I, Sanz J, Medina H, Garcia M . Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Imaging. 2013; 6(2):185-94. DOI: 10.1161/CIRCIMAGING.112.000153. View

16.

Lee W, Fang C, Chen Y, Fang H, Chen H, Liu W . Left Atrial or Left Atrial Appendage Thrombus Resolution After Adjustment of Oral Anticoagulant Treatment. J Stroke Cerebrovasc Dis. 2018; 28(1):90-96. DOI: 10.1016/j.jstrokecerebrovasdis.2018.09.015. View

17.

Lip G, Hammerstingl C, Marin F, Cappato R, Meng I, Kirsch B . Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016; 178:126-34. DOI: 10.1016/j.ahj.2016.05.007. View

18.

Birnie D, Healey J, Wells G, Verma A, Tang A, Krahn A . Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013; 368(22):2084-93. DOI: 10.1056/NEJMoa1302946. View

19.

Calkins H, Willems S, Gerstenfeld E, Verma A, Schilling R, Hohnloser S . Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med. 2017; 376(17):1627-1636. DOI: 10.1056/NEJMoa1701005. View

20.

Hohnloser S, Camm J, Cappato R, Diener H, Heidbuchel H, Mont L . Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J. 2019; 40(36):3013-3021. PMC: 6754569. DOI: 10.1093/eurheartj/ehz190. View